Blog
RSS FeedPosted by Michael Wonder on 24 Jun 2020
NeuroRx and Relief Therapeutics announce fast track designation granted by the FDA to RLF-100 (aviptadil) for the treatment of respiratory distress in COVID-19
24 June 2020 - At the FDA’s request, NeuroRx is submitting an expanded access policy enabling physicians to request RLF-100 for ...
Posted by Michael Wonder on 24 Jun 2020
Big pharma is taking big money from U.S. tax payers to find a coronavirus vaccine — and charge whatever they want for it
24 June 2020 - Congress must act now to ensure that COVID-19 vaccines and treatments are affordable. ...
Posted by Michael Wonder on 24 Jun 2020
Renibus Therapeutics receives FDA fast track designation for RBT-9 treatment in COVID-19
23 June 2020 - Renibus Therapeutics announced today that it has been granted fast track designation by the FDA for RBT-9 ...
Posted by Michael Wonder on 23 Jun 2020
FDA maintains the pace of meeting its goals on applications for medical products during the pandemic
23 June 2020 - One of the challenges facing the FDA during the COVID-19 pandemic is how to ensure the ...
Posted by Michael Wonder on 21 Jun 2020
Coronavirus attacks the lungs. A federal agency just halted funding for new lung treatments.
19 June 2020 - The shift, quietly disclosed on a government website, highlights how the Trump administration is favouring development of ...
Posted by Michael Wonder on 18 Jun 2020
FDA takes additional action to harness real world data to inform COVID-19 response efforts
18 June 2020 - Today the U.S. Food and Drug Administration has taken an additional step in harnessing real-world data to ...
Posted by Michael Wonder on 17 Jun 2020
A mad scramble to stock millions of malaria pills, likely for nothing
16 June 2020 - Before the F.D.A. withdrew its waiver to stockpile the drugs as coronavirus treatments, the Trump administration had ...
Posted by Michael Wonder on 17 Jun 2020
Most coronavirus tests cost about $100. Why did one cost $2,315?
16 June 2020 - U.S. health care prices are unregulated, opaque and unpredictable. When Congress required insurers to cover COVID-19 testing, ...
Posted by Michael Wonder on 15 Jun 2020
COVID-19 update: FDA revokes emergency use authorisation for chloroquine and hydroxychloroquine
15 June 2020 - Today, the U.S. FDA revoked the emergency use authorisation that allowed for chloroquine phosphate and hydroxychloroquine sulphate ...
Posted by Michael Wonder on 15 Jun 2020
The pandemic claims new victims: prestigious medical journals
14 June 2020 - Two major study retractions in one month have left researchers wondering if the peer review process is ...
Posted by Michael Wonder on 11 Jun 2020
Cell and gene therapies: FDA official on COVID-19 impact
10 June 2020 - Speaking at a session on cell and gene therapies at BIO Digital on Monday, a top US ...
Posted by Michael Wonder on 11 Jun 2020
U.S. FDA Commissioner says agency seeks fast review of COVID-19 products
11 June 2020 - The U.S. FDA is seeking to review treatments and tests for COVID-19 “as fast as we can” ...
Posted by Michael Wonder on 11 Jun 2020
Rare disease therapy development and access remain top FDA priorities during COVID-19
11 June 2020 - The FDA’s work on behalf of people with rare diseases is more important than ever as these ...
Posted by Michael Wonder on 10 Jun 2020
Price limits will scare off COVID-19 vaccine makers, Fauci warns
10 June 2020 - More than one vaccine will be needed, Fauci says. ...
Posted by Michael Wonder on 09 Jun 2020
The US government's supply of the only proven COVID-19 drug runs out at the end of the month
8 June 2020 - The US government's current supply of remdesivir, the only drug known to work against COVID-19, will ...